Posted by Michael Wonder on 27 Jul 2019
Pfizer's Besponsa, Takeda's Zejula likely to get insurance coverage
26 July 2019 - Pfizer's Besponsa, a B-cell lymphoblastic leukaemia treatment, and Takeda's Zejula, an ovarian cancer treatment, have passed the threshold of the HIRA’s drug price assessment committee.
HIRA held a meeting of the committee on Thursday and concluded Besponsa and Zejula as eligible for insurance benefit.
Both drugs received sales approval from the Ministry of Food and Drug Safety in the first-half year.
